TY - JOUR
T1 - Early clinical study of an intermittent schedule for maytansine (NSC-153858)
AU - Eagan, R. T.
AU - Ingle, J. N.
AU - Rubin, J.
AU - Frytak, S.
AU - Moertel, C. G.
PY - 1978
Y1 - 1978
N2 - Maytansine, an ansa macrolide, was evaluated in an early clinical trial in 40 adult patients with various solid tumors. Severe nausea and vomiting, sometimes associated with watery diarrhea and abdominal cramps, and liver function abnormalities, mainly elevation of serum glutamic-oxaloacetic transaminase levels, together constituted what we considered dose-limiting toxicity. Mild hematologic toxicity (mainly thrombocytopenia), neurotoxicity, and possibly cardiac toxicity were also noted. No antitumor effect was seen. An iv dose of 0.750 mg/m2 on days 1, 3, and 5 (total dose, 2.25 mg/m2) repeated every 4 weeks is recommended for Phase II trials.
AB - Maytansine, an ansa macrolide, was evaluated in an early clinical trial in 40 adult patients with various solid tumors. Severe nausea and vomiting, sometimes associated with watery diarrhea and abdominal cramps, and liver function abnormalities, mainly elevation of serum glutamic-oxaloacetic transaminase levels, together constituted what we considered dose-limiting toxicity. Mild hematologic toxicity (mainly thrombocytopenia), neurotoxicity, and possibly cardiac toxicity were also noted. No antitumor effect was seen. An iv dose of 0.750 mg/m2 on days 1, 3, and 5 (total dose, 2.25 mg/m2) repeated every 4 weeks is recommended for Phase II trials.
UR - http://www.scopus.com/inward/record.url?scp=0018090648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018090648&partnerID=8YFLogxK
U2 - 10.1093/jnci/60.1.93
DO - 10.1093/jnci/60.1.93
M3 - Article
C2 - 628025
AN - SCOPUS:0018090648
SN - 1931-857X
VL - 60
SP - 93
EP - 96
JO - Unknown Journal
JF - Unknown Journal
IS - 1
ER -